Abstract
Background Studies have already shown that many environmental factors are associated with COVID-19 incidence. However, none have studied a very large set of socio-economic indicators and analysed to what extent these factors could highlight populations at high risk for COVID-19. We propose here a new approach, a socio-economic wide study, to pinpoint subgroups with a high incidence of COVID-19, and illustrated this approach using hospitalized cases in Paris area.
Methods We extracted 303 socio-economic indicators from French census data for the 855 residential units in Paris and assessed their association with COVID-19 hospitalization risk. We then fitted a predictive model using a penalized regression on these indicators to predict the incidence of patient hospitalization for COVID-19 in Paris.
Findings The most associated indicator was income, corresponding to the 3rd decile of the population (OR= 0.11, CI95% [0.05; 0.20]). A model including only income achieves a high performance in both the training set (AUC=0.78, CI95%: 0.72-0.85) and the test set (AUC=0.79 (CI95%: 0.71-0.87). Overall, the 45% most deprived areas gathered 86% of the areas with a high incidence of COVID-19 hospitalized cases.
Interpretation During the first wave of the epidemic, income predicted Paris areas at risk for a high incidence of patients hospitalized for COVID-19 with a high performance. Socio-economic wide association studies, collecting passively data from hospitalized cases, therefore not necessitating any effort for health caregivers, is of particular interest in such a period of hospital overcrowding as it provides real-time indirect information on populations having high COVID-19 incidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
H. Countouris received funding from Canceropole Ile-de-France to develop the geolocalization method used for this study. AS Jannot received funding for this project from the COVID sponsorship (mecenat Collecte Crise Covid) of AP-HP Centre Universite de Paris.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the institutional review board (authorization number IRB 00011591) from the Scientific and Ethical Committee from the AP-HP (Assistance Publique Hopitaux de Paris).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Aggregated data at IRIS level and programming codes are available on request from the corresponding author after approval by the institutional review board (authorization number IRB 00011591) from the Scientific and Ethical Committee from the AP-HP (Assistance Publique Hopitaux de Paris) for research purposes in line with French health data regulation.
